Clinical trial
A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
NCT03357471 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 3, 2017
- Completion date
- July 2, 2018
- Enrollment
- 70 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.
active ankylosing spondylitis, active psoriatic arthritis, moderate and severe active rheumatoid arthritis, moderately to severely active crohn's disease